Oncopeptides AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	62.47	31.65	35.22	8.36	118.3	-
Revenue Growth (YoY)	130.75%	-10.14%	321.54%	-92.94%	-	-
Cost of Revenue	1.33	2.66	-1.08	0.01	53.12	-
Gross Profit	61.14	28.99	36.3	8.35	65.17	-
Selling, General & Admin	202.24	197.28	188.48	142.2	873.81	654.19
Research & Development	110.22	121.19	106.95	217.66	679.93	866.21
Other Operating Expenses	-5.78	-6.9	-6.34	-4.57	3.9	-
Operating Expenses	306.69	311.57	289.09	355.29	1,558	1,520
Operating Income	-245.55	-282.59	-252.79	-346.94	-1,492	-1,520
Interest Expense	-32.31	-12.66	-5.79	-0.88	-0.95	-1.49
Interest & Investment Income	8.2	8.2	8.59	2.62	0.49	0.32
Currency Exchange Gain (Loss)	2.84	2.84	1.54	8.96	71.54	-70.87
Other Non Operating Income (Expenses)	-	0	-	-	0	-
EBT Excluding Unusual Items	-266.82	-284.21	-248.45	-336.24	-1,421	-1,592
Gain (Loss) on Sale of Assets	-	-	-	-1.44	-	-
Pretax Income	-266.82	-284.21	-248.45	-337.68	-1,421	-1,592
Income Tax Expense	1.02	0.4	0.66	0.27	8.95	2.25
Net Income	-267.84	-284.61	-249.11	-337.95	-1,430	-1,595
Net Income to Common	-267.84	-284.61	-249.11	-337.95	-1,430	-1,595
Shares Outstanding (Basic)	216	166	90	82	75	62
Shares Outstanding (Diluted)	216	166	90	82	75	62
Shares Change (YoY)	58.45%	84.14%	9.80%	9.33%	20.72%	20.63%
EPS (Basic)	-1.24	-1.71	-2.76	-4.11	-19.00	-25.57
EPS (Diluted)	-1.24	-1.71	-2.76	-4.11	-19.00	-25.57
Free Cash Flow	-228.28	-260.93	-279.61	-423.02	-1,517	-1,314
Free Cash Flow Per Share	-1.06	-1.57	-3.09	-5.14	-20.14	-21.06
Gross Margin	97.88%	91.59%	103.06%	99.93%	55.09%	-
Operating Margin	-393.09%	-892.91%	-717.74%	-4152.44%	-1261.64%	-
Profit Margin	-428.78%	-899.29%	-707.30%	-4044.90%	-1209.11%	-
Free Cash Flow Margin	-365.46%	-824.47%	-793.89%	-5063.03%	-1282.16%	-
EBITDA	-243.05	-280.12	-250.35	-344.93	-1,491	-1,519
D&A For EBITDA	2.49	2.47	2.44	2.01	1.72	1.72
EBIT	-245.55	-282.59	-252.79	-346.94	-1,492	-1,520

Source: S&P Global Market Intelligence. Standard template. Financial Sources.